Debashis Sarker

2024

A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases

Plummer, R., Greystoke, A., Naylor, G., Sarker, D., Anam, A. K., Prenen, H., Teuwen, L. A., Van Cutsem, E., Dekervel, J., Haugk, B., Ness, T., Bhoi, S., Jensen, M., Morris, T., Baumann, P., Sjögren, N., Tunblad, K., Wallberg, H., Öberg, F. & Evans, T. R. J., 2024, In: Journal of Hepatocellular Carcinoma. 11, p. 2033-2047 15 p.

Research output: Contribution to journal › Article › peer-review

Open Access

2023

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

Kristeleit, R., Plummer, R., Jones, R., Carter, L., Blagden, S., Sarker, D., Arkenau, T., Evans, T. R. J., Danson, S., Symeonides, S. N., Veal, G. J., Klencke, B. J., Kowalski, M. M. & Banerji, U., 27 Jul 2023, In: British journal of cancer. 129, 1, p. 38-45 8 p.

Research output: Contribution to journal › Article › peer-review

Open Access

18 Citations (Scopus)

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Jones, R., Plummer, R., Moreno, V., Carter, L., Roda, D., Garralda, E., Kristeleit, R., Sarker, D., Arkenau, T., Roxburgh, P., Walter, H. S., Blagden, S., Anthoney, A., Klencke, B. J., Kowalski, M. M. & Banerji, U., 15 Jan 2023, In: Clinical Cancer Research. 29, 2, p. 331-340 10 p.

Research output: Contribution to journal › Article › peer-review

Open Access

21 Citations (Scopus)

CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells

Samain, R., Maiques, O., Monger, J., Lam, H., Candido, J., George, S., Ferrari, N., Kohihammer, L., Lunetto, S., Varela, A., Orgaz, J. L., Vilardell, F., Olsina, J. J., Matias-Guiu, X., Sarker, D., Biddle, A., Balkwill, F. R., Eyles, J., Wilkinson, R. W. & Kocher, H. M. & 3 others, Calvo, F., Wells, C. M. & Sanz-Moreno, V., 2023, In: Science Advances. 9, 42, adi0244.

Research output: Contribution to journal › Article › peer-review

Open Access

6 Citations (Scopus)

Next-generation sequencing and molecular therapy

Morton, C., Sarker, D. & Ross, P., Jan 2023, In: Clinical Medicine, Journal of the Royal College of Physicians of London. 23, 1, p. 65-69 5 p.

Research output: Contribution to journal › Article › peer-review

Open Access

4 Citations (Scopus)

Next-generation sequencing and molecular therapy

Morton, C., Sarker, D. & Ross, P., Jan 2023, In: Clinical medicine (London, England). 23, 1, p. 65-69 5 p.

Research output: Contribution to journal › Article › peer-review

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer

Propper, D. J., Gao, F., Saunders, M. P., Sarker, D., Hartley, J. A., Spanswick, V. J., Lowe, H. L., Hackett, L. D., Ng, T. T., Barber, P. R., Weitsman, G. E., Pearce, S., White, L., Lopes, A., Forsyth, S. & Hochhauser, D., 19 Jan 2023, In: British journal of cancer. 128, 2, p. 245-254 10 p.

Research output: Contribution to journal › Article › peer-review

Open Access

4 Citations (Scopus)

Revitalising cancer trials post-pandemic: time for reform

Morton, C., Sullivan, R., Sarker, D., Posner, J. & Spicer, J., 12 Apr 2023, In: British journal of cancer. 128, 8, p. 1409-1414 6 p.

Research output: Contribution to journal › Article › peer-review

Open Access

5 Citations (Scopus)

2022

Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

Ryoo, B.-Y., Palmer, D. H., Park, S. R., Rimassa, L., Sarker, D., Daniele, B., Steinberg, J., López, B. & Lim, H. Y., Mar 2022, In: CLINICAL DRUG INVESTIGATION. 42, 3, p. 283

Research output: Contribution to journal › Article › peer-review

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

KEYNOTE-224 investigators, May 2022, In: European Journal of Cancer. 167, p. 1-12 12 p.

Research output: Contribution to journal › Article › peer-review

Open Access

65 Citations (Scopus)

2021

A phase I, open-label, dose-finding study of GSK2636771, a PI3Kb inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer

Sarker, D., Dawson, N. A., Aparicio, A. M., Dorff, T. B., Pantuck, A. J., Vaishampayan, U. N., Henson, L., Vasist, L., Roy-Ghanta, S., Gorczyca, M., York, W., Ganji, G., Tolson, J. & de Bono, J. S., 1 Oct 2021, In: Clinical Cancer Research. 27, 19, p. 5248-5257 10 p.

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison

Trojan, J., Mollon, P., Daniele, B., Marteau, F., Martín, L., Li, Y., Xu, Q., Piscaglia, F., Zaucha, R., Sarker, D., Lim, H. Y. & Venerito, M., May 2021, In: ADVANCES IN THERAPY. 38, 5, p. 2472-2490 19 p.

Research output: Contribution to journal › Article › peer-review

Open Access

6 Citations (Scopus)

Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation-Results from the MACPIE-I study

Kundalia, K., Hakeem, A., Papoulas, M., Mcphail, M., Reddy, S., Peddu, P., Kibriya, N., Atkinson, S., Prachalias, A., Srinivasan, P., Heaton, N., Sarker, D., Ross, P., Zen, Y. & Menon, K., Oct 2021, In: European Journal of Surgical Oncology. 47, 10, p. 2571-2578 8 p.

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Pancreatic cancer exposome profile to aid early detection and inform prevention strategies

Monroy-Iglesias, M. J., Dolly, S., Sarker, D., Thillai, K., Van Hemelrijck, M. & Santaolalla, A., Apr 2021, In: Journal of Clinical Medicine. 10, 8, 1665.

Research output: Contribution to journal › Article › peer-review

Open Access

File

6 Citations (Scopus)

119 Downloads (Pure)

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C. C., Godbert, Y. & Sarker, D. & 5 others, Miller, S. G., Clifford, C., Zhang, H., Turner, C. D. & Taylor, M. H., Aug 2021, In: The Lancet Diabetes and Endocrinology. 9, 8, p. 491-501 11 p.

Research output: Contribution to journal › Article › peer-review

239 Citations (Scopus)

Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer

Hashimoto, A., Sarker, D., Reebye, V., Jarvis, S., Sodergren, M. H., Kossenkov, A., Sanseviero, E., Raulf, N., Vasara, J., Andrikakou, P., Meyer, T., Huang, K. W., Plummer, R., Chee, C. E., Spalding, D., Pai, M., Khan, S., Pinato, D. J., Sharma, R. & Basu, B. & 11 others, Palmer, D., Ma, Y. T., Evans, J., Habib, R., Martirosyan, A., Elasri, N., Reynaud, A., Rossi, J. J., Cobbold, M., Habib, N. A. & Gabrilovich, D. I., 15 Nov 2021, In: Clinical Cancer Research. 27, 21, p. 5961-5978 18 p.

Research output: Contribution to journal › Article › peer-review

Open Access

61 Citations (Scopus)

2020

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

Plummer, R., Dua, D., Cresti, N., Drew, Y., Stephens, P., Foegh, M., Knudsen, S., Sachdev, P., Mistry, B. M., Dixit, V., McGonigle, S., Hall, N., Matijevic, M., McGrath, S. & Sarker, D., 18 Aug 2020, In: British Journal of Cancer. 123, 4, p. 525-533 9 p.

Research output: Contribution to journal › Article › peer-review

Open Access

50 Citations (Scopus)

MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Sarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., Huang, K.-W., Palmer, D. H., Ma, Y. T., Evans, T. R. J., Spalding, D. R. C., Pai, M., Sharma, R., Pinato, D. J., Spicer, J., Hunter, S., Kwatra, V., Nicholls, J. P., Collin, D. & Nutbrown, R. & 16 others, Glenny, H., Fairbairn, S., Reebye, V., Voutila, J., Dorman, S., Andrikakou, P., Lloyd, P., Felstead, S., Vasara, J., Habib, R., Wood, C., Saetrom, P., Huber, H. E., Blakey, D. C., Rossi, J. J. & Habib, N., 1 Aug 2020, In: Clinical Cancer Research. 26, 15, p. 3936-3946 11 p.

Research output: Contribution to journal › Article › peer-review

Open Access

103 Citations (Scopus)

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

Sarker, D., 5 Feb 2020, In: BMJ Open. 10, 2, e034527.

Research output: Contribution to journal › Article › peer-review

Open Access

12 Citations (Scopus)

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Sarker, D., 1 Dec 2020, In: Nature Communications. 11, 1, 4841.

Research output: Contribution to journal › Article › peer-review

Open Access

142 Citations (Scopus)

Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study

Sollie, S., Santaolalla, A., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 28 Feb 2020, In: Frontiers in oncology. 10, p. 263 263.

Research output: Contribution to journal › Article › peer-review

Open Access

File

7 Citations (Scopus)

131 Downloads (Pure)

The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy

Webb, T. E., Davies, M., Maher, J. & Sarker, D., 1 Sept 2020, In: Clinical and Translational Radiation Oncology. 24, p. 123-126 4 p.

Research output: Contribution to journal › Article › peer-review

Open Access

File

5 Citations (Scopus)

131 Downloads (Pure)

Validity of whole genomes sequencing results in neoplasms in precision medicine

Echejoh, G., Liu, Y., Chung-Faye, G., Charlton, J., Moorhead, J., Clark, B., Davidson, P., Sarker, D., Ross, P. & Ooft, M. L., 2020, (Accepted/In press) In: Journal of Clinical Pathology.

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

2019

Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study

Sollie, S., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Santaolalla, A., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 29 Aug 2019, (E-pub ahead of print) In: BMC Cancer. 19, 1, 858.

Research output: Contribution to journal › Article › peer-review

Open Access

File

30 Citations (Scopus)

82 Downloads (Pure)

First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma

Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J. W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H. Y., Mazzaferro, V., Trojan, J., Zhu, A. X., Yoon, J. H., Sharma, S., Lin, Z. Z., Chan, S. L., Faivre, S., Feun, L. G. & Yen, C. J. & 15 others, Dufour, J. F., Palmer, D. H., Llovet, J. M., Manoogian, M., Tugnait, M., Stransky, N., Hagel, M., Kohl, N. E., Lengauer, C., Sherwin, C. A., Schmidt-Kittler, O., Hoeflich, K. P., Shi, H., Wolf, B. B. & Kang, Y. K., 1 Dec 2019, In: Cancer discovery. 9, 12, p. 1696-1707 12 p.

Research output: Contribution to journal › Article › peer-review

175 Citations (Scopus)

Hepatocellular Carcinoma as a Complication of Vascular Disease of the Liver After Fontan Procedure

Mazzarelli, C., Cannon, M. D., Hudson, M., Heaton, N., Sarker, D., Kane, P., Quaglia, A. & Suddle, A., 1 Feb 2019, In: Hepatology. 69, 2, p. 911-913 3 p.

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

2018

ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma

Sarker, D., 2018, In: Annals of Oncology.

Research output: Contribution to journal › Article › peer-review

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

O’Brien, M. E. R., Sarker, D., Bhosle, J., Thillai, K., Yap, T. A., Uttenreuther-Fischer, M., Pemberton, K., Jin, X., Wiebe, S., De Bono, J. & Spicer, J., 7 Aug 2018, (E-pub ahead of print) In: Cancer Chemotherapy and Pharmacology.

Research output: Contribution to journal › Article › peer-review

Open Access

File

4 Citations (Scopus)

113 Downloads (Pure)

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents

Jordan, E. J., Spicer, J. & Sarker, D., 21 Sept 2018, In: Oncotarget. 9, 74, p. 33961-33971 11 p.

Research output: Contribution to journal › Article › peer-review

Open Access

File

2 Citations (Scopus)

99 Downloads (Pure)

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Massard, C., Azaro, A., Soria, J. C., Lassen, U., Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A. & Rodon, J., 1 Sept 2018, In: Annals of Oncology. 29, 9, p. 1911-1917 7 p.

Research output: Contribution to journal › Article › peer-review

Open Access

File

106 Citations (Scopus)

320 Downloads (Pure)

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S. L., Knox, J., Daniele, B., Webber, A. L., Ebbinghaus, S. W., Ma, J., Siegel, A. B. & KEYNOTE-224 investigators & 31 others, Cheng, A.-L., Kudo, M., Alistar, A., Asselah, J., Blanc, J.-F., Borbath, I., Cannon, T., Chung, K., Cohn, A., Cosgrove, D. P., Damjanov, N., Gupta, M., Karino, Y., Karwal, M., Kaubisch, A., Kelley, R., Van Laethem, J.-L., Larson, T., Lee, J., Li, D., Manhas, A., Manji, G. A., Numata, K., Parsons, B., Paulson, A. S., Pinto, C., Ramirez, R., Ratnam, S., Rizell, M., Rosmorduc, O. & Sada, Y., 1 Jul 2018, In: The Lancet Oncology. 19, 7, p. 940-952

Research output: Contribution to journal › Article › peer-review

1928 Citations (Scopus)

PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer

Sarker, D., 2018, In: Health Technology Assessment.

Research output: Contribution to journal › Article › peer-review

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Abou-Alfa, G. K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H. Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W. P., Chen, Z., Hubner, R. A., Meyer, T., Sun, W., Harding, J. J., Hollywood, E. M. & Ma, J. & 7 others, Wan, P. J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y. & Chen, L.-T., 1 Jun 2018, In: Annals of Oncology. 29, 6, p. 1402-1408

Research output: Contribution to journal › Article › peer-review

Open Access

154 Citations (Scopus)

2017

Hepatocellular Carcinoma in Perinatally Acquired HIV and HBV Coinfection: A Case Report

Sarker, D., 2017, In: Pediatric Infectious Disease Journal.

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series

de Vito, C., Sarker, D., Ross, P., Heaton, N. & Quaglia, A., Nov 2017, In: Virchows Archiv : an international journal of pathology. 471, 5, p. 619-629 11 p.

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

2016

Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?

Thillai, K., Lam, H., Sarker, D. & Wells, C. M., 11 Nov 2016, In: Oncotarget. 8, 8, p. 14173-14191 19 p.

Research output: Contribution to journal › Article › peer-review

Open Access

File

30 Citations (Scopus)

267 Downloads (Pure)

Does dose affect tumour response in phase I oncology trials of non-cytotoxic agents?

Ghosh, J., Lazaridis, G., Viney, Z., Verma, H., Sheriff, I., Wang, Y., Moller, H., Spicer, J. F. & Sarker, D., 1 Oct 2016, In: Annals of Oncology. 27, p. vi131

Research output: Contribution to journal › Article › peer-review

Open Access

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem

Ziogas, D. C., Papadatos-Pastos, D., Thillai, K., Korantzis, I., Chowdhury, R., Suddle, A., O'Grady, J., Al-Khadimi, G., Allen, N., Heaton, N., Ross, P. J. & Sarker, D., 10 Sept 2016, In: European Journal of Gastroenterology and Hepatology. 29, 1, p. 48-55

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Thillai, K., Ross, P. & Sarker, D., 15 Feb 2016, (E-pub ahead of print) In: World journal of gastrointestinal oncology. 8, 2, p. 173-85 13 p.

Research output: Contribution to journal › Article › peer-review

Open Access

File

27 Citations (Scopus)

304 Downloads (Pure)

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

Josephs, D. H. & Sarker, D., 21 Feb 2016, In: Translational Oncogenomics.

Research output: Contribution to journal › Article › peer-review

Open Access

File

41 Citations (Scopus)

198 Downloads (Pure)

Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells

Alrifai, D., Sarker, D. & Maher, J., Feb 2016, In: Immunopharmacology and Immunotoxicology. 38, 1, p. 50-60

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

2015

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., Mazina, K., Lin, R., Wu, J., Fredrickson, J., Spoerke, J. M., Lackner, M. R., Yan, Y., Friedman, L. S., Kaye, S. B. & Derynck, M. K. & 2 others, Workman, P. & de Bono, J. S., 1 Jan 2015, In: Clinical Cancer Research. 21, 1, p. 77-86 10 p.

Research output: Contribution to journal › Article › peer-review

Open Access

267 Citations (Scopus)

Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System

Mills, L., Ramage, J., Prachalias, A., Srinivasan, P., Menon, K., Heaton, N., Quaglia, A., Vivian, G., Sarker, D., Ross, P., Basuroy, R. & Srirajaskanthan, R., 2015, In: Neuroendocrinology. 102, 1-2, p. 103-103

Research output: Contribution to journal › Article › peer-review

Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?

Basuroy, R., Sarker, D., Quaglia, A., Srirajaskanthan, R. & Ramage, J., Aug 2015, In: INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY. 2, 3, p. 201-215

Research output: Contribution to journal › Article › peer-review

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours

Spicer, J., Baird, R., Suder, A., Cresti, N., Corbacho, J. G., Hogarth, L., Frenkel, E., Matsumoto, S., Kawabata, I., Donaldson, K., Posner, J., Sarker, D., Jodrell, D. & Plummer, R., 31 Jan 2015, In: European Journal of Cancer. 51, 2, p. 137-145 9 p.

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

2014

FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer

Papadatos-Pastos, D., Thillai, K., Rabbie, R., Ross, P. & Sarker, D., Oct 2014, In: EXPERT REVIEW OF ANTICANCER THERAPY. 14, 10, p. 1115-1125 11 p.

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets

Britton, D., Zen, Y., Quaglia, A., Selzer, S., Mitra, V., Löβner, C., Jung, S., Böhm, G., Schmid, P., Prefot, P., Hoehle, C., Koncarevic, S., Gee, J., Nicholson, R., Ward, M., Castellano, L., Stebbing, J., Zucht, H. D., Sarker, D. & Heaton, N. & 1 others, Pike, I., 26 Mar 2014, In: PLoS ONE. 9, 3, 20 p., e90948.

Research output: Contribution to journal › Article › peer-review

Open Access